Alpha Tau Medical Ltd. (DRTS)

Market Cap	185.10M
Revenue (ttm)	n/a
Net Income (ttm)	-31.75M
Shares Out	70.38M
EPS (ttm)	-0.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,595
Open	2.650
Previous Close	2.620
Day's Range	2.630 - 2.650
52-Week Range	1.750 - 4.387
Beta	0.93
Analysts	Strong Buy
Price Target	8.00 (+204.18%)
Earnings Date	May 19, 2025

About DRTS

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending clinical studies for brain and other cancers. The company is headquartered in Jerusalem, Israel.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 125
• Stock Exchange: NASDAQ
• Ticker Symbol: DRTS
• Website: https://www.alphatau.com

Analyst Forecast

According to 2 analysts, the average rating for DRTS stock is "Strong Buy." The 12-month stock price forecast is $8.0, which is an increase of 204.18% from the latest price.

Price Target

$8.0

(204.18% upside)

Analyst Consensus: Strong Buy